

Pancreatic and Thyroid Cancer Related to Exenatide and Liraglutide Treatment: A Post-marketing Analysis of Spontaneous Cases Reported in EudraVigilance Database

Ghanshyam Mali¹, Vivek Ahuja², Kiran Dubey¹



¹ Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India – 110062

² Medical Affairs and Global Pharmacovigilance, Sun Pharmaceutical Industries Limited, Gurugram, India 122015

Abstract

The use of glucagon-like peptide-1 (GLP-1) analogues has been linked with the risk of pancreatic and thyroid cancer. Exenatide and liraglutide carry a boxed warning in their pack insert regarding the possible association with medullary thyroid cancer and caution regarding acute pancreatitis. Our objective was to detect from EudraVigilance database, a signal of pancreatic and thyroid cancer with exenatide and liraglutide treatments in patients with diabetes.

Methods: Herein, we analyzed all spontaneous cases of pancreatic and thyroid cancer reported with exenatide and liraglutide in EudraVigilance database from their inception till 30th January 2020. A case/noncase method was used to detect the association, calculating proportional reporting ratios (PRRs) and their 95% confidence interval (CI) as a measure of disproportionality.

Results: There were 4349 cases of pancreatic cancer and 1697 cases of thyroid cancer in the 6,665,794 reports recorded in EudraVigilance during the study period. From the inception of exenatide and liraglutide, the total numbers of pancreatic cancer cases identified with them in EudraVigilance database were 222 and 313, respectively, and the total numbers of thyroid cancer cases were 36 and 53, respectively. Significant disproportionality was observed between pancreatic cancer and exenatide and liraglutide with PRR of 36.4 (95% CI, 31.8-41.7) and 42.4 (95% CI, 37.7- 47.6), respectively. Disproportionality was also observed between thyroid cancer and exenatide and liraglutide with PRR of 14.7 (95% CI, 10.5-20.4) and 17.6 (95% CI, 13.4-23.2), respectively.

Conclusions: This study based on EudraVigilance database further confirms signals for both thyroid and pancreatic cancer with exenatide and liraglutide.



Biography:

Ghanshyam Mali has completed his Master of Pharmacy at the age of 24 years from Manipal University Karnataka, India and currently pursuing his PhD from Jamia Hamdard, deemed to be University, New Delhi. He has more than 5 years of experience in Medical Writing in Pharmaceutical Organization. He has published 3 papers in reputed journals.

[13th International Conference and Exhibition on Pharmacovigilance & Drug Safety;](#)
Zurich, Switzerland- July 27-28, 2020.

Abstract Citation:

Ghanshyam Mali, Pancreatic and Thyroid Cancer Related to Exenatide and Liraglutide Treatment: A Post-marketing Analysis of Spontaneous Cases Reported in EudraVigilance Database, 13th International Conference and Exhibition on Pharmacovigilance & Drug Safety; Zurich, Switzerland- July 27-28,2020.

(<https://pharmacovigilance.pharmaceuticalconferences.com/abstract/2020/pancreatic-and-thyroid-cancer-related-to-exenatide-and-liraglutide-treatment-a-post-marketing-analysis-of-spontaneous-cases-reported-in-eudravigilance-database>)